Reducing symptoms of depression and anxiety in adolescents with inflammatory bowel disease in order to improve quality of life and the clinical course of disease

Completed

• Conditions: angststoornissen; 10017969; Inflammatory Bowel Disease (IBD) / Chronic bowel inflammation; 10027946

• Registration Number: NL-OMON44382
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

-Patients between 10-25 years with diagnosed IBD
-Informed consent or assent by patients and (if necessary) parents

Exclusion Criteria

voor screeningsfase:
• IBD patients with parental report of mental retardation
• IBD patients receiving psychopharmacological treatment (antidepressants or benzodiazepines) for anxiety of depression
• No mastery of the Dutch language
• IBD patients with diagnosed Bipolar disorder, Schizophrenia/psychotic disorder, Autism spectrum disorders, Obsessive-compulsive disorder, Posttraumatic stress disorder/Acute stress disorder, or Substance use disorder
• Physician reported substance abuse (alcohol, drugs) in the past month
• Parental report of Selective mutism
• IBD patients already participating in an (psychological of psychopharmacological) intervention study
• Current psychological treatment
• 8 sessions of protocolled cognitive behavioral therapy during the last year ;voor inclusie in RCT:
-IBD patients with scores for a major depressive disorder or an anxiety disorder
-IBD patients with a urgent need for immediate referral because of other psychological or behavioral problems than depression or anxiety

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main outcome is reduction in symptoms of depression. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary psychological outcomes are reduction in symptoms of anxiety, quality<br /><br>of life, psychosocial functioning, illness perception, cognitive coping,<br /><br>quality of sleep, parental anxiety and/or depression, stressful life-events,<br /><br>family functioning and demographic factors. Secondary medical outcomes are<br /><br>presence of clinical relapse, IBD activity scores, necessity of surgical<br /><br>intervention, treatment adherence, health care utilization, disease phenotype,<br /><br>treatment strategy, immune status (RNA expression profiles) and immunological<br /><br>activity (blood lymfocyt profiles).</p><br>